Status:
COMPLETED
Post-Marketing Surveillance Study of OTEZLA
Lead Sponsor:
Amgen
Conditions:
Psoriasis
Eligibility:
All Genders
Brief Summary
To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathic...
Eligibility Criteria
Inclusion
- \- Patients who have received a diagnosis of either of the following diseases and have received OTEZLA for the first time will be included in this survey.
- Psoriasis vulgaris that is with an inadequate response to topical therapies
- Psoriasis arthropathica
Exclusion
- N/A
Key Trial Info
Start Date :
September 5 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 20 2022
Estimated Enrollment :
1086 Patients enrolled
Trial Details
Trial ID
NCT03284879
Start Date
September 5 2017
End Date
March 20 2022
Last Update
September 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tugi dermatology clinic
Kitakyushu, Fukuoka, Japan, 804-0081